199 Bay Street
Suite 4000
Toronto, ON M5L 1A9
Canada
416 854 8884
https://www.fsdpharma.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Zeeshan Saeed | Founder, CEO, President & Executive Co-Chairman | 209.61k | N/A | 1970 |
Mr. Anthony John Durkacz | Founder & Executive Co-Chairman | 209.61k | N/A | 1976 |
Mr. Nathan Coyle CPA | Chief Financial Officer | 167.79k | N/A | 1981 |
Dr. Lakshmi P. Kotra BPHARM, Ph.D. | CEO of Lucid & Director | 136.27k | N/A | 1971 |
Ms. Maryann Adesso | Corporate Secretary | N/A | N/A | N/A |
Randell Mack | President of FSD BioSciences | N/A | N/A | N/A |
Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical & Scientific Affairs of Lucid | 103.86k | N/A | N/A |
Mr. Kevin Cassidy | Vice President of Quality-Lucid | 136.36k | N/A | N/A |
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.
FSD PHARMA B’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.